LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 4 of total 4

Search options

  1. Article ; Online: COVID-19 and nutriceutical therapies, especially using zinc to supplement antimicrobials.

    Butters, Desley / Whitehouse, Michael

    Inflammopharmacology

    2020  Volume 29, Issue 1, Page(s) 101–105

    Abstract: The nutritional status of a patient can be critical for the efficacy of other pharmaceuticals, especially organic antibiotics, to treat viral pandemics. There may be political and scientific difficulties in achieving a constructive synergy of nutritional ...

    Abstract The nutritional status of a patient can be critical for the efficacy of other pharmaceuticals, especially organic antibiotics, to treat viral pandemics. There may be political and scientific difficulties in achieving a constructive synergy of nutritional and prescribed allopathic remedies. For adequate treatment, timelines may need to extend well beyond eliminating viral proliferation, e.g., with vaccines, to include the goals of (a) reducing post-viral fatigue, (b) promoting earliest recovery, and (c) future resistance in often poorly nourished patients, e.g., obese (!). Many trace minerals (TM) and vitamins may need to be replenished. This review focusses only upon zinc to illustrate some problems in rectifying these TM deficiencies affecting the balance between continued ill-health ('illth') or regaining optimal physical and mental wellbeing. Ultimately, this is a matter of behaviour, lifestyle, and informed choice(s). See Hetzel and McMichael 1959.
    MeSH term(s) Anti-Infective Agents/administration & dosage ; Anti-Infective Agents/therapeutic use ; COVID-19/drug therapy ; Dietary Supplements ; Humans ; Nutritional Status ; Pandemics ; SARS-CoV-2 ; Zinc/administration & dosage ; Zinc/metabolism ; Zinc/therapeutic use
    Chemical Substances Anti-Infective Agents ; Zinc (J41CSQ7QDS)
    Keywords covid19
    Language English
    Publishing date 2020-11-16
    Publishing country Switzerland
    Document type Journal Article ; Review
    ZDB-ID 1080058-x
    ISSN 1568-5608 ; 0925-4692
    ISSN (online) 1568-5608
    ISSN 0925-4692
    DOI 10.1007/s10787-020-00774-8
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 3274: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Conditional pharmacology/toxicology V: ambivalent effects of thiocyanate upon the development and the inhibition of experimental arthritis in rats by aurothiomalate (Myocrysin®) and metallic silver.

    Whitehouse, Michael / Butters, Desley / Vernon-Roberts, Barrie

    Inflammopharmacology

    2013  Volume 21, Issue 4, Page(s) 291–300

    Abstract: This article discusses the bizarre and contrary effects of thiocyanate, the major detoxication product of hydrogen cyanide inhaled from tobacco smoke or liberated from cyanogenic foods, e.g. cassava. Thiocyanate both (1) promotes inflammatory disease in ... ...

    Abstract This article discusses the bizarre and contrary effects of thiocyanate, the major detoxication product of hydrogen cyanide inhaled from tobacco smoke or liberated from cyanogenic foods, e.g. cassava. Thiocyanate both (1) promotes inflammatory disease in rats and (2) facilitates the anti-inflammatory action of historic metal therapies based on gold (Au) or silver (Ag) in three models of chronic polyarthritis in rats. Low doses of nanoparticulate metallic silver (NMS) preparations, i.e. zerovalent silver (Ag°) administered orally, suppressed the mycobacterial ('adjuvant')-induced arthritis (MIA) in rats. Similar doses of cationic silver, Ag(I), administered orally as silver oxide or soluble silver salts were inactive. By contrast, NMS only inhibited the development of the collagen-induced arthritis (CIA) and pristane-induced arthritis (PIA) in rats when thiocyanate was also co-administered in drinking water. These (a) arthritis-selective and (b) thiocyanate-inducible effects of Ag° were also observed in some previous, and now extended, studies with the classic anti-arthritic drug, sodium aurothiomalate (ATM, Myocrisin(®)) and its silver analogue (STM), administered subcutaneously to rats developing the same three forms of polyarthritis. In the absence of either Ag° or ATM, thiocyanate considerably increased the severity of the MIA, CIA and PIA, i.e. acting as a pro-pathogen. Hitherto, thiocyanate was considered relatively harmless. This may not be true in rats/people with immuno-inflammatory stress and concomitant leukocyte activation. Collectively, these findings show how the drug action of a xenobiotic might be determined by the nature (and severity) of the experimental inflammation, as an example of conditional pharmacology. They also suggest that an incipient toxicity, even of normobiotics such as thiocyanate, might likewise be modulated beneficially by well-chosen xenobiotics (drugs, nutritional supplements, etc.), i.e. conditional toxicology (Powanda 1995). Thus, both the disease and the environment may determine (1) the therapeutic action and/or (2) adverse effect(s) of xenobiotics--and even some normobiotics.
    MeSH term(s) Animals ; Antirheumatic Agents/pharmacology ; Antirheumatic Agents/therapeutic use ; Antirheumatic Agents/toxicity ; Arthritis, Experimental/chemically induced ; Arthritis, Experimental/drug therapy ; Arthritis, Experimental/microbiology ; Drug Synergism ; Drug Therapy, Combination ; Gold Sodium Thiomalate/pharmacology ; Gold Sodium Thiomalate/therapeutic use ; Gold Sodium Thiomalate/toxicity ; Nanoparticles ; Rats ; Silver/pharmacology ; Silver/therapeutic use ; Silver/toxicity ; Species Specificity ; Thiocyanates/pharmacology ; Thiocyanates/therapeutic use ; Thiocyanates/toxicity
    Chemical Substances Antirheumatic Agents ; Thiocyanates ; Gold Sodium Thiomalate (12244-57-4) ; Silver (3M4G523W1G) ; thiocyanate (O748SU14OM)
    Language English
    Publishing date 2013-05-19
    Publishing country Switzerland
    Document type Journal Article ; Research Support, Non-U.S. Gov't ; Review
    ZDB-ID 1080058-x
    ISSN 1568-5608 ; 0925-4692
    ISSN (online) 1568-5608
    ISSN 0925-4692
    DOI 10.1007/s10787-013-0173-9
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 3274: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: Beyond conventional DMARDs: extending TNF-regulant therapies to the vast majority/less privileged who do need them.

    Butters, Desley / Whitehouse, Michael

    International journal of rheumatic diseases

    2009  Volume 12, Issue 4, Page(s) 299–306

    Abstract: This article is a plea to find (better) ways to extend the benefits of anti-cytokine therapies to ensure they will become available as widely as possible. Pessimistically, this will probably involve substituting more affordable, although somewhat less ... ...

    Abstract This article is a plea to find (better) ways to extend the benefits of anti-cytokine therapies to ensure they will become available as widely as possible. Pessimistically, this will probably involve substituting more affordable, although somewhat less specific, non-biological agents for present target-specific bio-DMARDs (disease-modifying antirheumatic drugs) to ensure far wider distribution of benefits. Optimistically, new developments in technology and bio-engineering might dramatically reduce costs of present 'biological' therapies. (The antibiotics we now take for granted were once also horrendously expensive.). Pragmatically, one goal for this mission should include seriously pursuing more research and pilot clinical trials of non-protein combination therapies able to control: (i) TNF or other pro-inflammatory cytokines; and also (ii) other mediators sustaining chronic inflammation (-->pain, effusion, fibrosis, porosis, etc.). This can be immediately facilitated by drawing upon the immense resources of non-prescription Asia-Pacific traditional therapies--particularly when these have already been shown to either reduce TNF synthesis or control TNF-induced responses in preclinical studies. Could this be a major goal for the next decade, helping rectify some of the omissions of the current Bone & Joint Decade 2000-2010?
    MeSH term(s) Antibodies, Monoclonal/economics ; Antibodies, Monoclonal/therapeutic use ; Antirheumatic Agents/economics ; Antirheumatic Agents/therapeutic use ; Clinical Trials as Topic ; Drug Design ; Drug Therapy, Combination ; Health Care Costs ; Health Services Accessibility/economics ; Health Services Accessibility/organization & administration ; Humans ; Immunologic Factors/economics ; Immunologic Factors/therapeutic use ; Inflammation Mediators/therapeutic use ; Medicine, East Asian Traditional ; Rheumatic Diseases/drug therapy ; Rheumatic Diseases/economics ; Tumor Necrosis Factor-alpha/antagonists & inhibitors
    Chemical Substances Antibodies, Monoclonal ; Antirheumatic Agents ; Immunologic Factors ; Inflammation Mediators ; Tumor Necrosis Factor-alpha
    Language English
    Publishing date 2009-12
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 2426924-4
    ISSN 1756-185X ; 1756-1841
    ISSN (online) 1756-185X
    ISSN 1756-1841
    DOI 10.1111/j.1756-185X.2009.01427.x
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6098: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: Queries about vaccines containing squalene.

    Beck, Frances / Butters, Desley / Matsumoto, Gary / Whitehouse, Michael

    Immunology and cell biology

    2010  Volume 88, Issue 5, Page(s) 497–499

    MeSH term(s) Adjuvants, Immunologic/adverse effects ; Animals ; Humans ; Influenza, Human/prevention & control ; Squalene/adverse effects ; Squalene/immunology ; Vaccines/chemistry ; Vaccines/immunology
    Chemical Substances Adjuvants, Immunologic ; Vaccines ; Squalene (7QWM220FJH)
    Language English
    Publishing date 2010-02-16
    Publishing country United States
    Document type Letter ; Review
    ZDB-ID 284057-1
    ISSN 1440-1711 ; 0818-9641
    ISSN (online) 1440-1711
    ISSN 0818-9641
    DOI 10.1038/icb.2010.10
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Uc I Zs.175: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top